Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,849 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Completed Not applicable Interventional

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

NCT03796052
View directory record Official record
Conditions
Ichthyosis, Pruritus
Interventions
Avena Sativa Skincare Regimen
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

NCT07242638
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata
Interventions
Abrocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

NCT06945458
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KT-621
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
12
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiofrequency and Pulsed Electromagnetic Field Treatment of Skin Laxity of the Mon Pubis, Labia and Vaginal Introitus

NCT02770287
View directory record Official record
Conditions
Skin Laxity
Interventions
Venus Freeze Diamond Polar
Device
Lead sponsor
Venus Concept
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis

NCT03083730
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Narrow band UVB treatment (NB-UVB)
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

NCT02670330
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101-6.0 cream
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
1 Month and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

NCT05721937
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 22, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

NCT06718101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lutikizumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Fountain Hills, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed No phase listed Observational

Gait Analysis in MPS IVA

NCT01920828
View directory record Official record
Conditions
MPS IVA, Morquio Syndrome
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Year and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

NCT07229430
View directory record Official record
Conditions
Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
Interventions
ULTRAFORMER MPT PLUS, Ulthera System
Device
Lead sponsor
CLASSYS Inc.
Industry
Eligibility
30 Years to 65 Years
Enrollment
273 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Charlotte, North Carolina • Wilmington, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

NCT01457430
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 22, 2026, 4:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mechanical Coring to Achieve Directional Skin Tightening

NCT04910945
View directory record Official record
Conditions
Skin Tightening, Healthy Volunteers
Interventions
VENUS AIME (RoboCor)
Device
Lead sponsor
Venus Concept
Industry
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Los Altos, California • San Jose, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT03513328
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

NCT00783965
View directory record Official record
Conditions
Skin Carcinoma
Interventions
tazarotene, placebo
Drug · Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 22, 2026, 4:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

NCT03847389
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Clobetasol propionate 0.05% Topical Oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Sanford, Florida • Savannah, Georgia • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 22, 2026, 4:53 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Wearable Ultrasound Patch for Breast Imaging

NCT07186491
View directory record Official record
Conditions
Breast Cancer, Breast Abnormalities, Breast Lesion, Breast Asymmetry
Interventions
Wearable Ultrasound Patch
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity and Volume Restoration

NCT04176068
View directory record Official record
Conditions
Skin Laxity
Interventions
calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)
Combination Product
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 22, 2026, 4:53 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT07016750
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
KB803, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

NCT00838708
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
SRD174 Cream, vehicle cream
Drug · Other
Lead sponsor
Serentis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2009 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BTL-785F Device for Improving the Structure of Facial Muscles

NCT05524740
View directory record Official record
Conditions
Wrinkle
Interventions
BTL-785-7
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The PREFORM Study: Rotational Fractional Resection for Submental Contouring

NCT03966924
View directory record Official record
Conditions
Skin Laxity, Lipodystrophy
Interventions
Rotational fractional resection (1.5mm Diameter Device)
Device
Lead sponsor
Recros Medica, Inc.
Industry
Eligibility
30 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 22, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Results available

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 22, 2026, 4:53 AM EDT